112 related articles for article (PubMed ID: 22236353)
1. Toxicity associated with epirubicin treatments in a large case series of dogs.
Marrington AM; Killick DR; Grant IA; Blackwood L
Vet Comp Oncol; 2012 Jun; 10(2):113-23. PubMed ID: 22236353
[TBL] [Abstract][Full Text] [Related]
2. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004).
Kim SE; Liptak JM; Gall TT; Monteith GJ; Woods JP
J Am Vet Med Assoc; 2007 Nov; 231(10):1550-7. PubMed ID: 18021000
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma.
Khanna C; Lund EM; Redic KA; Hayden DW; Bell FW; Goulland EL; Klausner JS
J Am Vet Med Assoc; 1998 Oct; 213(7):985-90. PubMed ID: 9776993
[TBL] [Abstract][Full Text] [Related]
4. CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
Heading KL; Brockley LK; Bennett PF
Aust Vet J; 2011 Apr; 89(4):109-16. PubMed ID: 21418164
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
[TBL] [Abstract][Full Text] [Related]
6. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma.
Elliott JW; Cripps P; Marrington AM; Grant IA; Blackwood L
Vet Comp Oncol; 2013 Sep; 11(3):185-98. PubMed ID: 22372620
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.
Lee YR; Kang MH; Park HM
Can Vet J; 2015 Jun; 56(6):571-4. PubMed ID: 26028676
[TBL] [Abstract][Full Text] [Related]
9. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide association study of epirubicin-induced leukopenia in Japanese patients.
Srinivasan Y; Sasa M; Honda J; Takahashi A; Uno S; Kamatani N; Kubo M; Nakamura Y; Zembutsu H
Pharmacogenet Genomics; 2011 Sep; 21(9):552-8. PubMed ID: 21799462
[TBL] [Abstract][Full Text] [Related]
11. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer.
Havsteen H; Bertelsen K; Gadeberg CC; Jacobsen A; Kamby C; Sandberg E; Sengeløv L
Gynecol Oncol; 1996 Nov; 63(2):210-5. PubMed ID: 8910629
[TBL] [Abstract][Full Text] [Related]
13. Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
Ogilvie GK; Moore AS; Chen C; Ciekot PA; Atwater SW; Bergman PJ; Walters LM
J Am Vet Med Assoc; 1994 Aug; 205(4):570-3. PubMed ID: 7961092
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study.
Mason SL; Grant IA; Elliott J; Cripps P; Blackwood L
J Small Anim Pract; 2014 Aug; 55(8):391-8. PubMed ID: 24920169
[TBL] [Abstract][Full Text] [Related]
15. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors.
Vail DM; Kravis LD; Cooley AJ; Chun R; MacEwen EG
Cancer Chemother Pharmacol; 1997; 39(5):410-6. PubMed ID: 9054954
[TBL] [Abstract][Full Text] [Related]
16. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
17. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
O'Connor R; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A; Kennedy S; Fennelly D; Clynes M; Crown J
Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Ogura T; Hagihara A; Iwasa S
Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
[TBL] [Abstract][Full Text] [Related]
19. Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin.
Kelly JM; Belding BA; Schaefer AK
Vet Comp Oncol; 2010 Jun; 8(2):81-6. PubMed ID: 20579320
[TBL] [Abstract][Full Text] [Related]
20. Case-control study to evaluate risk factors for the development of sepsis (neutropenia and fever) in dogs receiving chemotherapy.
Sorenmo KU; Harwood LP; King LG; Drobatz KJ
J Am Vet Med Assoc; 2010 Mar; 236(6):650-6. PubMed ID: 20225976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
